1. |
Das N, Dhanawat M, Sushant K. An overview on antiepileptic drugs. Drug Discov Ther, 2012, 6(4):178-193.
|
2. |
Brill J, Klocke R, Paul D, et al. A novel epileptic and ataxic Cacna2 d2 mutant of the mouse. Biol Chem, 2004, 279(8):7322-7330.
|
3. |
Cojocaru IM, Cojocaru M. Reactions of the immune system in epilepsy. Maedica Buchar, 2010, 5 (3):201-206.
|
4. |
Binder DK, Carson MJ. Glial cells as primary therapeutic targets for epilepsy. Neurochem Int, 2013, 63(7):635-637.
|
5. |
臧玉静, 赵春玲. 与癫痫有关的细胞信号通路的研究现状. 临床与病理杂志, 2014, 34(1):99-105.
|
6. |
Zeng LH, Xu L, Gutmann DH, et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol, 2008, 63(4):444-453.
|
7. |
Muncy J, Butler IJ, Koenig MK. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol, 2009, 24(4):477.
|
8. |
Backman SA, Stambolic V, Suzuki A,et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet, 2001, 29(4):396-403.
|
9. |
冯丽娟, 卢雪峰, 何庆泗,等.胃癌组织中mTOR 和HIF-1α的表达及血管生成.中国现代普通外科进展, 2009, 12(12):1036-1039.
|
10. |
Ghosh HS, McBurney M, Robbins PD. SITR1 negatively regulates the mammalian target of rapamycin. PLoS One, 2010, 5(2):e9199.
|
11. |
Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev, 2004, 18(16):1926-1945.
|